Answers are grounded in this paper and cite their sources.
Periodontitis causes alveolar bone loss, systemic inflammation, and gut dysbiosis, which are poorly resolved by conventional local therapies. Oral gavage of D-enantiomeric human β-defensin 3 (D-hBD3) sustains intestinal homeostasis and ameliorates periodontitis, yet the detailed mechanisms remain unclear. This study provides supporting evidence for a plausible gut–oral axis mechanism underlying D-hBD3-mediated periodontitis protection. A ligature-induced mouse periodontitis model was utilized to assess therapeutic outcomes of D-hBD3 oral gavage, D-hBD3 combined with a Dectin-1 antagonist, and fecal microbiota transplantation. Evaluations covered alveolar bone loss, serum lipopolysaccharide and interleukin-6 levels, and intestinal barrier integrity. Intestinal macrophage polarization, tight junction protein expression, and gut microbiota composition were analyzed, while multi-omics and correlation analyses characterized host and microbial tryptophan metabolic alterations and core regulatory molecules. D-hBD3 treatment and microbiota transplantation reduced alveolar bone resorption, restored intestinal barrier integrity, and alleviated systemic inflammation. Pharmacological Dectin-1 inhibition partially abolished these protective effects, supporting the involvement of Dectin-1 signaling in this protective phenotype. D-hBD3 activates intestinal macrophage Dectin-1 signaling, promotes M2 polarization, and upregulates tight junction proteins, thereby remodeling gut microbiota by enriching Bifidobacterium and depleting Akkermansia and Escherichia . D-hBD3 remodels tryptophan metabolism, elevating indole-3-carboxaldehyde and suppressing serotonin pathway metabolites. These microbial ligands positively correlate with Dectin-1 and extracellular matrix remodeling genes and negatively correlate with pro-inflammatory Stat1 . D-hBD3 ameliorates periodontitis via the gut–oral axis through a Dectin-1-associated gut microbiota–tryptophan metabolism cascade, revealing the promising potential of gut-targeted defensins as adjunctive periodontitis therapeutics.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: